Similarly, in a population-based cohort study of more than 200,000 patients, there was no difference in the risk of UTI events between patients initiating SGLT2 inhibitors compared to those initiating DPP-4 inhibitors or GLP1 RA treatment (79). This evidence concerns the gene GCG and bacterial urinary tract infection.